Evolent Health, Inc.: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Aug 3, 2022 and accepted by EDGAR at Aug 3, 2022, 16:03 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-04-01 to 2022-06-30 | $319.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2022-01-01 to 2022-06-30 | $617.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2022-04-01 to 2022-06-30 | $3.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2022-01-01 to 2022-06-30 | $7.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-04-01 to 2022-06-30 | $59.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2022-01-01 to 2022-06-30 | $117.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-04-01 to 2022-06-30 | −$4.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | −$7.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-04-01 to 2022-06-30 | $2.1m | us-gaap:InterestExpense |
| Interest expense | 6 months2022-01-01 to 2022-06-30 | $4.4m | us-gaap:InterestExpense |
| Income tax | 3 months2022-04-01 to 2022-06-30 | −$184.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2022-01-01 to 2022-06-30 | $1.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-04-01 to 2022-06-30 | −$4.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-01-01 to 2022-06-30 | −$9.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-04-01 to 2022-06-30 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-01-01 to 2022-06-30 | −$0.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | −$0.11 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-04-01 to 2022-06-30 | 90,071,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-01-01 to 2022-06-30 | 89,792,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | −$43.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2022-06-30 | $193.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $423.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $1.30bn | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $342.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-06-30 | $690.8m | us-gaap:Liabilities |
| Long-term debt | At period end2022-06-30 | $283.1m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2022-06-30 | $613.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628908-22-000098. Last ingested by Listed: Nov 15, 2026, 04:22 ET. Listed shows no prices and gives no investment advice.